From Research to Healthcare Delivery, Patt’s Versatility is Cited by ASCO
DESTINY-Breast04 trial marks a major advance for advanced HER2-low breast cancer, offering new hope and treatment options for patients.
Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, conducted interview after interview during the ASCO annual meeting to explain the significance of the meeting's largest trial, DESTINY-Breast04. The trial will be a game changer for patients with advanced HER2-low breast cancer.
Click here to read the full article.
Click here to read the full article.